Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Mais filtros










Intervalo de ano de publicação
1.
Lipids Health Dis ; 21(1): 61, 2022 Jul 21.
Artigo em Inglês | MEDLINE | ID: mdl-35864531

RESUMO

BACKGROUND: It is important to identify patients at increased risk of worsening of left ventricular ejection fraction (LVEF) after a myocardial infarction (MI). We aimed to identify the association of various potential biomarkers with LVEF impairment after an MI in South American patients. METHODS: We studied adult patients admitted to a University Hospital and diagnosed with an acute MI. Plasma concentrations of high-sensitivity C-reactive protein (hsCRP), proprotein convertase subtilisin/kexin type 9 (PCSK9), N-terminal prohormone of brain natriuretic peptide (NT-proBNP) and heart-type fatty-acid-binding protein (FABP3) were determined in samples drawn shortly after the event. Participants had a follow-up visit at least 45 days after the event. The primary endpoint was defined as any decline in LVEF at follow-up relative to baseline. RESULTS: The study included 106 patients (77.4% men, 22.6% women), mean age was 64.1, mean baseline LVEF was 56.6, 19% had a prior MI. We obtained a follow-up evaluation in 100 (94.4%) of participants, mean follow-up time was 163 days. There was a significant correlation between baseline PCSK9 and hsCRP (r = 0.39, p < 0.001). Baseline hsCRP concentrations were higher in patients who developed the endpoint than in those who did not (32.1 versus 21.2 mg/L, p = 0.066). After multivariate adjustment, baseline PCSK9, male sex and age were significantly associated with impairment in LVEF. The absolute change in LVEF was inversely correlated with baseline hsCRP (standardized coefficient = - 0.246, p = 0.004). CONCLUSION: High plasma levels of PCSK9 and hsCRP were associated with early decreases in LVEF after an MI in Latin American patients.


Assuntos
Proteína C-Reativa , Infarto do Miocárdio , Adulto , Biomarcadores , Proteína C-Reativa/metabolismo , Estudos de Coortes , Feminino , Humanos , Masculino , Pessoa de Meia-Idade , Peptídeo Natriurético Encefálico , Fragmentos de Peptídeos , Pró-Proteína Convertase 9 , Volume Sistólico , Função Ventricular Esquerda
2.
Rev. colomb. cardiol ; 23(4): 270-276, jul.-ago. 2016. tab
Artigo em Espanhol | LILACS, COLNAL | ID: biblio-830291

RESUMO

Introducción y objetivos: La fibrilación auricular es la arritmia cardiaca más frecuente y una de las complicaciones más temidas es la embolia sistémica y/o el accidente cerebrovascular (ACV). En la actualidad se cuenta con diversas terapias antitrombóticas para prevención del primero, sin embargo, hay temor por complicaciones relacionadas con la anticoagulación, y aunque existen recomendaciones de diferentes guías de prácticas clínicas, continúa el uso subóptimo de la misma. El objetivo del estudio es describir datos clínicos, diagnósticos y terapéuticos de pacientes con fibrilación auricular que ingresan al servicio de urgencias, además, se realizó una correlación entre el riesgo de embolia sistémica y de sangrado con el tipo de terapia recibida. Métodos: Estudio descriptivo retrospectivo tipo serie de casos de pacientes con diagnóstico de la fibrilación auricular no valvular durante un año. Se reportan las frecuencias de comorbilidades, diagnósticos de ingreso y tipo de terapia específica. Resultados: Se incluyeron 98 pacientes, la media de edad fue 72 años, la falla cardiaca y la hipertensión arterial fueron las principales comorbilidades; el 92% tenían indicación de anticoagulación por la escala CHA2DS2VASc, 54% de estos pacientes no la venían recibiendo a pesar de que se calculó en la mayoría bajo riesgo de sangrado. El 5% de los pacientes ingresaron con diagnóstico de ACV isquémico y el 5% presentaban sobreanticogulación. Conclusión: Las características de nuestra población con la fibrilación auricular es similar a la descrita en la literatura, pero existe baja adherencia a las recomendaciones terapéuticas en anticoagulación.


Introduction and motivation: Atrial fibrillation is the most common cardiac arrhythmia. One of its most feared complications is the systemic embolism and/or the cerebrovascular accident (CVA) or stroke. Nowadays several antithrombotic therapies are available for the former; however, there are fears regarding complications related to anticoagulation, and even though recommendations of different clinical practice guidelines exist, blood-thinning drugs are still being underused. The goal of this study is to describe clinical, diagnostic and therapeutic data of patients admitted in the emergency room with atrial fibrillation; in addition, a correlation was made between the risk of systemic embolism and bleeding depending on the received treatment. Methods: Retrospective, descriptive study of case series of patients diagnosed with non-valvular atrial fibrillation during a year. Comorbidity frequencies, admission diagnoses and specific therapy types are reported. Results: 98 patients were included, average age was 72 years old, cardiac failure and high blood pressure were the main comorbidities; 92% showed an indication for anticoagulation therapy according to the CHA2DS2-VASc scale, 54% of those patients had not been receiving this therapy despite a low risk for bleeding was established for most of them. 5% of the patients received an admission diagnosis of ischemic stroke and 5% showed overanticoagulation. Conclusion: The characteristics of our sample with atrial fibrillation are similar to those described in the literature, but there is a low adherence to the treatment recommendations for anticoagulation therapy.


Assuntos
Humanos , Fibrilação Atrial , Anticoagulantes , Acidente Vascular Cerebral , Varfarina
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...